Cargando…
MYC and therapy resistance in cancer: risks and opportunities
The MYC transcription factor, encoded by the c‐MYC proto‐oncogene, is activated by growth‐promoting signals, and is a key regulator of biosynthetic and metabolic pathways driving cell growth and proliferation. These same processes are deregulated in MYC‐driven tumors, where they become critical for...
Autores principales: | Donati, Giulio, Amati, Bruno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627787/ https://www.ncbi.nlm.nih.gov/pubmed/36214609 http://dx.doi.org/10.1002/1878-0261.13319 |
Ejemplares similares
-
Two sides of the Myc-induced DNA damage response: from tumor suppression to tumor maintenance
por: Campaner, Stefano, et al.
Publicado: (2012) -
Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers
por: D’Avola, Annalisa, et al.
Publicado: (2023) -
SUMOylation of Myc-Family Proteins
por: Sabò, Arianna, et al.
Publicado: (2014) -
Oxidative stress enhances the therapeutic action of a respiratory inhibitor in MYC‐driven lymphoma
por: Donati, Giulio, et al.
Publicado: (2023) -
Targeting MYC in cancer therapy: RNA processing offers new opportunities
por: Koh, Cheryl M., et al.
Publicado: (2016)